Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities

Nicolò Girometti\textsuperscript{a,b}, Rachael Jones\textsuperscript{a}, Jeremy Levy\textsuperscript{a}, Sheena McCormack\textsuperscript{a,d}, Ann Sullivan\textsuperscript{a} and Tristan J. Barber\textsuperscript{a,e}

Renal toxicity in a 73-year-old male, using tenofovir/emtricitabine as preexposure prophylaxis, is described. Reduced renal reserve, a higher exposure to comedications and comorbidities can present a challenge when assessing the risks and benefits of tenofovir-based preexposure prophylaxis in the ageing population.

Preexposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), available as the fixed drug combination Truvada (Gilead Sciences, Inc., Foster City, California, USA), is highly effective in preventing HIV transmission [1–3] and is used increasingly as part of a combination prevention strategy in individuals at risk of acquiring HIV. A recent mathematical model showed the importance of PrEP as a single intervention able to outperform other isolated prevention strategies [4]. Tenofovir and emtricitabine were generally well tolerated, although drug-related gastrointestinal side-effects were reported more frequently in the first 12 weeks by those receiving active PrEP [1–3]. A significant decline in creatinine clearance (CrCl) was observed in 3–18\% of individuals [1–3.5], with a more significant drop of CrCl (below 60 ml/min) reported in 1\% of patients. Following cessation of therapy, CrCl normalized [5]. In PROUD, three of 275 (1.1\%) of the participants randomized to the immediate TDF/FTC arm interrupted the drug because of elevated serum creatinine. Two had documented comorbidities that may have influenced renal function; however, a relationship to TDF/FTC exposure could not be excluded. Renal dysfunction in the third case was attributed to recreational drug use [1].

We describe the challenge of managing a 73-year-old homosexual male with preexisting comorbidities, receiving daily TDF/FTC as PrEP and subsequently developing renal dysfunction requiring two isolated hospital admissions during follow-up. This male had a history of Crohn’s disease well controlled on mesalazine and was randomized to immediate PrEP as part of the PROUD study in August 2014, following normal baseline serum creatinine level (78 \text{\mu}mol/l), with an estimated CrCl of 90 ml/min (Cockcroft–Gault). No side-effects and full adherence to the medication were reported over the first 12 months following study entry, although, after 6 months, a decline in Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate (eGFR) was observed along with low level of proteinuria (\textlesssim 1+) detected by urine dipstick. Serum creatinine and urine testing were increased in frequency to monitor for early signs of possible TDF-induced tubulopathy [6]. During the first 18 months, an eGFR less than 50 ml/min was reported on two occasions (Table 1). In October 2015, the patient experienced a suspected flare of his Crohn’s, manifested as profuse diarrhoea and fatigue and resulting in significant dehydration and acute kidney injury (AKI). A rise in serum creatinine from 120 to 195 \text{\mu}mol/l and a resultant drop in CrCl from 52 to 30 ml/min were noted, along with severe hypokalemia (2.1 mmol/l) without hypophosphataemia (0.94 mmol/l). Following cessation of TDF/FTC, fluid resuscitation and treatment with intravenous antibiotics and potassium supplementation, renal function returned to baseline. Secondary tests were performed to investigate further the possible causes for renal dysfunction. A kidney ultrasound scan was unremarkable, whereas repeated urinary fractional excretion of electrolytes showed normal values of fractional excretion of sodium, which fell below 1\% during episode of AKI, suggesting dehydration as mechanism of renal failure. During trial management group meetings, it was agreed that the risk for the user to catch HIV outweighed the risk to his renal function; hence, the clinicians concurred with the participant’s preference to continue on PrEP. Nevertheless, following a reoccurrence of AKI triggered by another episode of persisting diarrhoea, in December 2015, the clinical team decided not to prescribe any more PrEP. On this occasion, creatinine levels rose again to 1.5 times their normal value and eGFR dropped down to 32 ml/min. After intravenous fluids correction, the renal function returned to pre-AKI levels.

The case describes an example of renal dysfunction in an older male with preexisting comorbidities and comedications on PrEP. It is known that people aged over 50 years, living with HIV, are at a higher risk of clinical progression [7] and in 2014, approximately 6\% of MSM, newly diagnosed with HIV in the UK, were over 50 years of age [8]. This data reinforce the validity of using PrEP in this selected population. Only 9\% (83/900) individuals in this age group were included in IperGAY and PROUD studies. As a result, there are no solid data on the long-term impact of PrEP in a HIV-negative population that is more prone to multiple comorbidities, polypharmacy and reduced renal function at baseline compared with younger counterparts. Also, an onset of TDF-induced tubular
dysfunction seems to correlate with older age in HIV-positive patients [9]. UK national guidelines for PrEP are not yet available, but renal monitoring is advised in a position statement [10]. It is possible that cases similar to this one will become more frequent with wider availability of PrEP, suggesting the urgent need for additional PrEP options that are less renally toxic. Further data on the long term renal monitoring of comorbidities in individuals aged over 50 years are needed to establish the optimal frequency of testing.

We encourage research on additional options for PrEP that are less renally toxic. A combination with tenofovir alafenamide and emtricitabine (TAF/FTC) has recently been licensed for treatment and may shortly be evaluated for PrEP [11]. TAF showed less detrimental effects on the kidneys and bones compared with TDF in HIV-positive patients [12]. Cabotegravir, a new long-acting injectable antiretroviral agent, showed significant protection in macaques [13], and there are plans to evaluate the efficacy in a noninferiority design compared with TDF/FTC. Due to favourable pharmacokinetics and promising preliminary in-vitro studies, maraviroc/lamivudine or raltegravir/lamivudine regimens [14] could be possible future options.

In an ideal world, potential PrEP users would have a choice of agents to select, and this choice could be individualized depending on age, comorbidities and preference. For now, options are limited. Patients in the deferred arm of the PROUD study had a particularly high risk of catching HIV infection (HIV incidence = 9.0/100 person-years). With this in mind, the balance of renal risk from daily tenofovir against a lifetime of infection with a nephrotropic virus and need for lifelong medication favoured PrEP at baseline. With the emergence of repeated AKI, the risk–benefit balance in this participant shifted towards interruption and discontinuation of tenofovir-based PrEP. This needs to be clearly explained to individuals so that they can make an informed decision about the risks, up to the point that a drug becomes clinically contraindicated.

**Acknowledgements**

All authors: PROUD study was founded by MRC Clinical Trials Unit at UCL – London, Public Health England and Gilead Sciences.

**Conflicts of interest**

There are no conflicts of interest.

*Chelsea & Westminster Hospital NHS Foundation Trust, London, UK; bDepartment of Medical Sciences and Surgery, Section of Infectious Diseases, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy; cImperial College Healthcare NHS Foundation Trust; dMedical Research Council, Clinical Trials Unit; and eImperial College London, London UK.*

Correspondence to Tristan J. Barber, Chelsea & Westminster Hospital NHS Foundation Trust, 4th Floor, St Stephen’s Centre, London, UK. Tel: +44 020 3315 6167; e-mail: tristan.barber@chelwest.nhs.uk

Received: 8 April 2016; revised: 3 May 2016; accepted: 16 May 2016.

**References**